ClinicalTrials.gg
CompletedNCT00800436Updated Dec 16, 2016Results posted

A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females

A Phase 1 interventional study of Herceptin in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-12-16.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
170th of 366
66 · median 61
Started
2008
with 13 others
Phase 1
21 of 374
3 open now
Registered
129th of 374
by date
Lead sponsor
31 of 374
Hoffmann-La Roche

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 170th largest by enrollment of the 366 interventional ones that give a count, is one of 14 that started in 2008, is one of 21 in phase 1, and was the 129th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This two-part study is designed to select the subcutaneous (SC) dose of Herceptin that results in comparable exposure to intravenous (IV) Herceptin in healthy male participants and in HER2-positive female participants. The study will also assess the safety and tolerability of the SC and IV formulations. In Part 1 of the study, four cohorts will be treated with a single dose of Herceptin as follows: Cohort 1 (6 milligrams per kilogram [mg/kg] IV in healthy male participants); Cohort 2 (6 mg/kg IV in HER2-positive female participants); Cohort 3 (6 mg/kg SC in healthy male participants); Cohort 4 (10 mg/kg SC in healthy male participants). An additional cohort of healthy volunteers (Cohort 5) will be opened if both SC dose levels from Cohorts 3 and 4 result in Herceptin exposures different from the target concentration produced by a single IV dose, or if the variability in pharmacokinetic (PK) parameter values cannot be used to define the target SC dose level. In Part 2 of the study, HER2-positive female participants will receive a single dose of SC Herceptin at the dose level defined in Part 1. Participants from Part 1 are eligible to enter Part 2 provided they receive the second (Part 2) study dose of Herceptin a minimum of 22 days after their first (Part 1) dose.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Participants (Part 1 only)

    • Males 18 to 45 to years of age
    • Baseline (LVEF) greater than (>) 60 percent (%)
  • -Positive Females (Parts 1 and 2)

    • Females greater than or equal to (≥) 18 years of age
    • (ECOG) performance status of 0
    • Previous non- operable primary invasive HER2-positive breast cancer
    • Baseline LVEF >55%

Exclusion criteria

Exclusion Criteria:

  • Healthy Participants (Part 1 only)

    • abnormalities in laboratory test results or
    • History of significant allergies, gastrointestinal, renal, hepatic, cardiovascular, or pulmonary disease
    • History of or allergic reaction, spontaneous or following drug administration
    • History of cardiac conditions
  • -Positive Females (Parts 1 and 2)

    • disease
    • Concurrent other requiring therapy of any modality which may interfere with PK investigations or result in unexpected toxicity
    • Use of Herceptin in previous 5 months
    • Serious cardiac illness
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Part 1: Cohort 1

    Healthy male participants will receive Herceptin 6 mg/kg IV on Day 1.

    Drug: Herceptin

  • Experimental
    Part 1: Cohort 2

    Female participants with HER2-positive breast cancer will receive Herceptin 6 mg/kg IV on Day 1.

    Drug: Herceptin

  • Experimental
    Part 1: Cohort 3

    Healthy male participants will receive Herceptin 6 mg/kg SC on Day 1.

    Drug: Herceptin

  • Experimental
    Part 1: Cohort 4

    Healthy male participants will receive Herceptin 10 mg/kg SC on Day 1.

    Drug: Herceptin

  • Experimental
    Part 1: Cohort 5

    Healthy male participants will receive Herceptin SC at an adjusted dose level based on preliminary PK analysis of Cohorts 1, 2, 3, and 4.

    Drug: Herceptin

  • Experimental
    Part 2: Cohort A

    Female participants with HER2-positive breast cancer will receive Herceptin SC at the dose level determined in Part 1.

    Drug: Herceptin

  • Experimental
    Part 2: Cohort B

    Female participants with HER2-positive breast cancer will receive Herceptin SC at an adjusted dose level based on preliminary PK analysis of Cohort A.

    Drug: Herceptin

Interventions

  • Herceptin will be administered IV or SC at various dosages (depending upon the cohort to which the participant is assigned) on Day 1.

    Also known as: Trastuzumab

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve Extrapolated to Infinity (AUCinf) of Trastuzumab

    AUCinf represents the area under the concentration-time curve of trastuzumab in serum over the time interval from 0 extrapolated to infinity. Values for AUCinf of trastuzumab were derived by non-compartmental analysis across all pharmacokinetic (PK) collections and expressed in days by micrograms per milliliter (days•μg/mL).

    Time frame: Predose (0 hours) and postdose from start of 1.5-hour infusion (1.5 and 3 hours for IV) (6, 8, 12 hours for SC) on Day 1; on Days 2, 3, 5, 8, 15, 22, 43, 85; additionally on Day 10 for SC and Day 35 for IV; and 5 months postdose (up to 5 months overall)

Secondary outcomes

  1. Trough Serum Concentration on Day 22 (CDay22) of Trastuzumab

    CDay22 of trastuzumab was derived from the single PK collection on Day 22 and expressed in micrograms per milliliter (μg/mL).

    Time frame: Day 22

  2. Maximum Observed Serum Concentration of Trastuzumab (Cmax)

    Cmax of trastuzumab was derived across all post-dose PK collections and expressed in μg/mL.

    Time frame: Postdose from start of 1.5-hour infusion (1.5 and 3 hours for IV) (6, 8, 12 hours for SC) on Day 1; on Days 2, 3, 5, 8, 15, 22, 43, 85; additionally on Day 10 for SC and Day 35 for IV; and 5 months postdose (up to 5 months overall)

  3. Time to Maximum Serum Concentration (Tmax) of Trastuzumab

    Tmax of trastuzumab was based on the Cmax derived across all post-dose PK collections and expressed in hours.

    Time frame: Postdose from start of 1.5-hour infusion (1.5 and 3 hours for IV) (6, 8, 12 hours for SC) on Day 1; on Days 2, 3, 5, 8, 15, 22, 43, 85; additionally on Day 10 for SC and Day 35 for IV; and 5 months postdose (up to 5 months overall)

  4. Terminal Elimination Half-Life (T1/2) of Trastuzumab

    T1/2 of trastuzumab was measured as the time required for trastuzumab concentration to decrease by one-half. T1/2 was derived across all PK collections and expressed in hours.

    Time frame: Postdose from start of 1.5-hour infusion (1.5 and 3 hours for IV) (6, 8, 12 hours for SC) on Day 1; on Days 2, 3, 5, 8, 15, 22, 43, 85; additionally on Day 10 for SC and Day 35 for IV; and 5 months postdose (up to 5 months overall)

07

Results

Posted Dec 16, 2016

Participant flow

Participant flow — Overall Study
MilestonePart 1: Cohort 1Part 1: Cohort 2Part 1: Cohort 3Part 1: Cohort 4Part 1: Cohort 5Part 2: Cohort APart 2: Cohort B
Started666662020
Completed665562020
Not completed0011000
Withdrew: Withdrawal by subject0011000

Outcome measures

PrimaryArea Under the Concentration-Time Curve Extrapolated to Infinity (AUCinf) of Trastuzumab

AUCinf represents the area under the concentration-time curve of trastuzumab in serum over the time interval from 0 extrapolated to infinity. Values for AUCinf of trastuzumab were derived by non-compartmental analysis across all pharmacokinetic (PK) collections and expressed in days by micrograms per milliliter (days•μg/mL).

Time frame:
Predose (0 hours) and postdose from start of 1.5-hour infusion (1.5 and 3 hours for IV) (6, 8, 12 hours for SC) on Day 1; on Days 2, 3, 5, 8, 15, 22, 43, 85; additionally on Day 10 for SC and Day 35 for IV; and 5 months postdose (up to 5 months overall)
Reported as:
Mean · days•μg/mL
Area Under the Concentration-Time Curve Extrapolated to Infinity (AUCinf) of Trastuzumab
days•μg/mLPart 1: Cohort 1Part 1: Cohort 2Part 1: Cohort 3Part 1: Cohort 4Part 1: Cohort 5Part 2: Cohort APart 2: Cohort B
Area Under the Concentration-Time Curve Extrapolated to Infinity (AUCinf) of Trastuzumab1610 ± 3031800 ± 2501350 ± 3202500 ± 5151960 ± 2442090 ± 6383550 ± 982
SecondaryTrough Serum Concentration on Day 22 (CDay22) of Trastuzumab

CDay22 of trastuzumab was derived from the single PK collection on Day 22 and expressed in micrograms per milliliter (μg/mL).

Time frame:
Day 22
Reported as:
Mean · μg/mL
Trough Serum Concentration on Day 22 (CDay22) of Trastuzumab
μg/mLPart 1: Cohort 1Part 1: Cohort 2Part 1: Cohort 3Part 1: Cohort 4Part 1: Cohort 5Part 2: Cohort APart 2: Cohort B
Trough Serum Concentration on Day 22 (CDay22) of Trastuzumab25.6 ± 12.127.5 ± 7.531.6 ± 12.051.4 ± 15.839.4 ± 5.537.8 ± 10.460.8 ± 22.0
SecondaryMaximum Observed Serum Concentration of Trastuzumab (Cmax)

Cmax of trastuzumab was derived across all post-dose PK collections and expressed in μg/mL.

Time frame:
Postdose from start of 1.5-hour infusion (1.5 and 3 hours for IV) (6, 8, 12 hours for SC) on Day 1; on Days 2, 3, 5, 8, 15, 22, 43, 85; additionally on Day 10 for SC and Day 35 for IV; and 5 months postdose (up to 5 months overall)
Reported as:
Mean · μg/mL
Maximum Observed Serum Concentration of Trastuzumab (Cmax)
μg/mLPart 1: Cohort 1Part 1: Cohort 2Part 1: Cohort 3Part 1: Cohort 4Part 1: Cohort 5Part 2: Cohort APart 2: Cohort B
Maximum Observed Serum Concentration of Trastuzumab (Cmax)150 ± 14.4185 ± 42.966.8 ± 11.4102 ± 17.282.0 ± 11.388.4 ± 33.3151 ± 58.6
SecondaryTime to Maximum Serum Concentration (Tmax) of Trastuzumab

Tmax of trastuzumab was based on the Cmax derived across all post-dose PK collections and expressed in hours.

Time frame:
Postdose from start of 1.5-hour infusion (1.5 and 3 hours for IV) (6, 8, 12 hours for SC) on Day 1; on Days 2, 3, 5, 8, 15, 22, 43, 85; additionally on Day 10 for SC and Day 35 for IV; and 5 months postdose (up to 5 months overall)
Reported as:
Median · hours
Time to Maximum Serum Concentration (Tmax) of Trastuzumab
hoursPart 1: Cohort 1Part 1: Cohort 2Part 1: Cohort 3Part 1: Cohort 4Part 1: Cohort 5Part 2: Cohort APart 2: Cohort B
Time to Maximum Serum Concentration (Tmax) of Trastuzumab1.65 (1.6 to 24.0)3.00 (1.55 to 24.0)156.00 (95.95 to 216.10)132.12 (96.00 to 216.00)96.00 (96.00 to 215.98)97.13 (47.93 to 216.60)96.05 (24.53 to 241.40)
SecondaryTerminal Elimination Half-Life (T1/2) of Trastuzumab

T1/2 of trastuzumab was measured as the time required for trastuzumab concentration to decrease by one-half. T1/2 was derived across all PK collections and expressed in hours.

Time frame:
Postdose from start of 1.5-hour infusion (1.5 and 3 hours for IV) (6, 8, 12 hours for SC) on Day 1; on Days 2, 3, 5, 8, 15, 22, 43, 85; additionally on Day 10 for SC and Day 35 for IV; and 5 months postdose (up to 5 months overall)
Reported as:
Mean · hours
Terminal Elimination Half-Life (T1/2) of Trastuzumab
hoursPart 1: Cohort 1Part 1: Cohort 2Part 1: Cohort 3Part 1: Cohort 4Part 1: Cohort 5Part 2: Cohort APart 2: Cohort B
Terminal Elimination Half-Life (T1/2) of Trastuzumab254 ± 32.2244 ± 69.2227 ± 55.9240 ± 34.4236 ± 43.9241 ± 48.1270 ± 80.1

Adverse events

Collected over From Baseline up to 5 months post-dose (up to 5 months overall). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Cohort 1—0/6 (0%)5/6 (83.3%)
Part 1: Cohort 2—0/6 (0%)6/6 (100%)
Part 1: Cohort 3—0/6 (0%)5/6 (83.3%)
Part 1: Cohort 4—0/6 (0%)5/6 (83.3%)
Part 1: Cohort 5—0/6 (0%)6/6 (100%)
Part 2: Cohort A—0/20 (0%)19/20 (95%)
Part 2: Cohort B—0/20 (0%)20/20 (100%)
Most frequent other events
Showing 10 of 116
Most frequent other events
EventPart 1: Cohort 1Part 1: Cohort 2Part 1: Cohort 3Part 1: Cohort 4Part 1: Cohort 5Part 2: Cohort APart 2: Cohort B
HeadacheNervous system disorders3/62/62/60/62/612/2014/20
Injection site discolourationGeneral disorders0/60/62/60/60/63/200/20
Infusion related reactionGeneral disorders2/60/60/60/60/60/200/20
Upper respiratory tract InfectionInfections and infestations0/60/61/62/61/64/205/20
Musculoskeletal painMusculoskeletal and connective tissue disorders2/61/60/60/60/60/201/20
DiarrhoeaGastrointestinal disorders2/60/60/60/60/66/202/20
Abdominal painGastrointestinal disorders2/60/60/60/60/60/200/20
AcneSkin and subcutaneous tissue disorders0/62/60/60/60/60/200/20
Injection site erythemaGeneral disorders0/60/61/60/60/64/202/20
LethargyNervous system disorders1/60/60/60/60/64/202/20

Baseline characteristics

Safety Population: All participants who received at least one dose of study medication, whether prematurely withdrawn from the study or not. The "Total" column (n=70) includes 4 female participants who were counted twice as they were treated in both Cohort 2 and Cohort A.

Age, Continuous
Age, Continuous(years)Part 1: Cohort 1Part 1: Cohort 2Part 1: Cohort 3Part 1: Cohort 4Part 1: Cohort 5Part 2: Cohort APart 2: Cohort BTotal
Mean22.7 ± 2.5846.2 ± 5.1925.7 ± 9.2923.0 ± 6.1622.0 ± 4.3450.7 ± 7.2151.6 ± 9.0441.2 ± 14.85
Gender
Gender(Participants)Part 1: Cohort 1Part 1: Cohort 2Part 1: Cohort 3Part 1: Cohort 4Part 1: Cohort 5Part 2: Cohort APart 2: Cohort BTotal
Female06000202046
Male606660024
08

Study locations

3 sites
  • East Bentleigh, VIC 3165, Australia
  • Christchurch, 8011, New Zealand
  • Grafton, 1150, New Zealand
09

References and documents

Publications

  • Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner B. Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol. 2013 Feb;53(2):192-201. doi: 10.1177/0091270012436560. PubMed 23436264 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2016, 7 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2008
First posted
Dec 2, 2008
Start
Nov 2008
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results first posted
Dec 16, 2016
Last update
Dec 16, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00800436
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 2, 2008
Start date
Nov 2008
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Dec 16, 2016
Last update
Dec 16, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion